Table 1.

Clinical, radiological, CSF data, and treatment and effect of treatment in CAA-I patients

Nr	Gender	Age	Symptoms	MB	LH	SS	Gado	Time LP	WBC	Protein	OCB	Treatment Effect
1	F	65	seizure, cognitive deficit	+++	0	0	NP	44 weeks	<3	0.45	No	No /
2	F	80	confusion, aphasia, cognitive deficit	+++	0	0	Mild lepto	6 weeks	<3	0.28	No	CS +
3	F	70	seizure, aphasia, cognitive deficit	3	2	FSS	Mild lepto	2 weeks	6	1.09	Yes	CS +
4	M	55	headache, cognitive and visual deficit	+++	0	0	Mild lepto	2 weeks	<3	0.54	No	CS/AZT/CPM +
5	F	78	apathy, gait disturb, confusion, cognitive deficit	+++	0	DSS	No	2 weeks	<3	1.12	NP	CS +
6	F	76	confusion, apathy, left neglect	+++	0	0	No	10 weeks	<3	0.31	No	CS +
7	M	71	apathy, confusion	+++	0	FSS	Mild lepto	4 weeks	<3	0.77	NP	CS +
8	M	66	confusion	+++	0	FSS	No	3 weeks	<3	0.43	NP	CS +
9	M	68	transient aphasia and faciobrachial paresthesias	+++	0	FSS	Mild lepto	0.5 week	<3	0.62	No	No /

Nr, patient number; MB, number of microbleeds; LH, lobar hemorrhage; SS, superficial siderosis; Gado, gadolinium enhancement on MRI; Time LP, delay between symptom onset and performance of lumbar puncture; WBC, number of white blood cells/mm³ in CSF; Protein, protein level (g/L) in CSF; OCB, oligoclonal bands; +++, innumerable (>25 microbleeds); FSS, focal superficial siderosis (superficial siderosis restricted to 3 or fewer sulci); DSS, disseminated superficial siderosis (superficial siderosis affecting at least 4 sulci); NP, not performed; Mild lepto, mild leptomeningeal enhancement; CS, corticosteroids; AZT, azathioprine; CPM, cyclophosphamide.